Literature DB >> 18090276

Reduced mortality and CD4 cell loss among carriers of the interleukin-10 -1082G allele in a Zimbabwean cohort of HIV-1-infected adults.

Christian Erikstrup1, Per Kallestrup, Rutendo B Zinyama-Gutsire, Exnevia Gomo, Anthony E Butterworth, Bente K Pedersen, Sisse R Ostrowski, Jan Gerstoft, Henrik Ullum.   

Abstract

OBJECTIVES: To evaluate the effect on HIV progression of single nucleotide polymorphisms in promoters of the genes for tumour necrosis factor (TNF)-alpha and interleukin (IL)-10 and known to influence cytokine production.
METHODS: Survival was documented for 4.3 years after baseline for 198 HIV-1-infected and 180 HIV-uninfected individuals from the Mupfure Schistosomiasis and HIV Cohort in rural Zimbabwe. Polymorphisms determined were -592C>A and -1082A>G for IL-10 and -238G>A and -308G>A for TNF-alpha. CD4 cell counts, plasma HIV RNA, soluble TNF receptor II (sTNF-rII), IL-8 and IL-10 were also measured.
RESULTS: Mortality was lower in carriers of the IL-10 -1082G high-producer allele (hazard ratio, 0.47; P < 0.01). CD4 cell count decrease in participants reporting for the follow-up at 3 years was attenuated in carriers of this allele (P < 0.01). In univariate analysis, plasma IL-10, IL-8, and sTNF-rII correlated negatively with CD4 cell count, positively with HIV RNA, and higher levels predicted mortality. In multivariate analysis only sTNF-rII was an independent predictor of HIV progression markers and mortality. Indeed, sTNF-rII predicted mortality (P < 0.01) at a level of significance comparable to HIV RNA (P < 0.01) and CD4 cell count (P < 0.05).
CONCLUSIONS: In carriers of IL-10 -1082G, an allele linked to increased IL-10 production, survival was doubled and CD4 cell decrease was attenuated compared with noncarriers. Only sTNF-rII and not plasma IL-10 was an independent predictor of HIV progression markers and mortality. This study supports immune activation as a driving force in HIV pathogenesis and indicates a protective role of IL-10 -1082G that should be evaluated in other cohorts.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 18090276     DOI: 10.1097/QAD.0b013e3282f153ed

Source DB:  PubMed          Journal:  AIDS        ISSN: 0269-9370            Impact factor:   4.177


  18 in total

1.  Pretreatment levels of soluble cellular receptors and interleukin-6 are associated with HIV disease progression in subjects treated with highly active antiretroviral therapy.

Authors:  Robert C Kalayjian; Rhoderick N Machekano; Nesrine Rizk; Gregory K Robbins; Rajesh T Gandhi; Benigno A Rodriguez; Richard B Pollard; Michael M Lederman; Alan Landay
Journal:  J Infect Dis       Date:  2010-06-15       Impact factor: 5.226

2.  Can an immune-regulatory vaccine prevent HIV infection?

Authors:  Tobias Boettler; Edecio Cunha-Neto; Jorge Kalil; Matthias von Herrath
Journal:  Expert Rev Anti Infect Ther       Date:  2012-03       Impact factor: 5.091

3.  Association of IL-10-promoter genetic variants with the rate of CD4 T-cell loss, IL-10 plasma levels, and breadth of cytotoxic T-cell lymphocyte response during chronic HIV-1 infection.

Authors:  Dshanta D Naicker; Bingxia Wang; Elena Losina; Jennifer Zupkosky; Susan Bryan; Shabashini Reddy; Manjeetha Jaggernath; Mammekwa Mokgoro; Philip J R Goulder; Daniel E Kaufmann; Thumbi Ndung'u
Journal:  Clin Infect Dis       Date:  2011-11-18       Impact factor: 9.079

4.  Lack of Association between Interleukin-10 Gene Promoter Polymorphisms with HIV Susceptibility and Progression to AIDS.

Authors:  Amitis Ramezani; Ebrahim Kalantar; Arezoo Aghakhani; Mohammad Banifazl; Maryam Foroughi; Soudabeh Hosseini; Ali Eslamifar; Ali Esmaeilzadeh; Minoo Mohraz
Journal:  Iran J Pathol       Date:  2015

5.  Interleukin gene polymorphisms and susceptibility to HIV-1 infection: a meta-analysis.

Authors:  Chrissa G Tsiara; Georgios K Nikolopoulos; Niki L Dimou; Katerina G Pantavou; Pantelis G Bagos; Benedicta Mensah; Michael Talias; Georgia G Braliou; Dimitra Paraskeva; Stefanos Bonovas; Angelos Hatzakis
Journal:  J Genet       Date:  2018-03       Impact factor: 1.166

6.  Effect of TNF-alpha genetic variants and CCR5 Delta 32 on the vulnerability to HIV-1 infection and disease progression in Caucasian Spaniards.

Authors:  Sergi Veloso; Montserrat Olona; Felipe García; Pere Domingo; Carlos Alonso-Villaverde; Montserrat Broch; Joaquim Peraire; Consuelo Viladés; Montserrat Plana; Enric Pedrol; Miguel López-Dupla; Carmen Aguilar; Mar Gutiérrez; Agathe Leon; Mariona Tasias; Josep Ma Gatell; Cristóbal Richart; Francesc Vidal
Journal:  BMC Med Genet       Date:  2010-04-26       Impact factor: 2.103

7.  Interleukin-10 promoter polymorphisms influence HIV-1 susceptibility and primary HIV-1 pathogenesis.

Authors:  Dshanta D Naicker; Lise Werner; Emil Kormuth; Jo-Ann Passmore; Koleka Mlisana; Salim Abdool Karim; Thumbi Ndung'u
Journal:  J Infect Dis       Date:  2009-08-01       Impact factor: 5.226

8.  Relationship between gene polymorphisms of two cytokine genes (TNF-α and IL-6) and occurring of lung cancers in the ethnic group Han of China.

Authors:  Jing Liang; Xiaolin Liu; Zhenqiang Bi; Beibei Yin; Junjuan Xiao; Hairong Liu; Yan Li
Journal:  Mol Biol Rep       Date:  2012-10-26       Impact factor: 2.316

9.  IL-10 is up-regulated in multiple cell types during viremic HIV infection and reversibly inhibits virus-specific T cells.

Authors:  Mark A Brockman; Douglas S Kwon; Daniel P Tighe; David F Pavlik; Pamela C Rosato; Jennifer Sela; Filippos Porichis; Sylvie Le Gall; Michael T Waring; Kristin Moss; Heiko Jessen; Florencia Pereyra; Daniel G Kavanagh; Bruce D Walker; Daniel E Kaufmann
Journal:  Blood       Date:  2009-04-13       Impact factor: 22.113

10.  HIV-1 Disease Progression and Survival in an Adult Population in Zimbabwe: Is There an Effect of the Mannose Binding Lectin Deficiency?

Authors:  Rutendo B L Zinyama-Gutsire; Charles Chasela; Per Kallestrup; Simbarashe Rusakaniko; Michael Christiansen; Bernard Ngara; Exnevia Gomo; Henrik Ullum; Christian Erikstrup; Hans O Madsen; Babill Stray-Pedersen; Peter Garred; Takafira Mduluza
Journal:  OMICS       Date:  2015-09
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.